High Content Screening using 3-D Models of Ovarian Cancer

使用卵巢癌 3D 模型进行高内涵筛查

• 批准号: 10006269
• 负责人: Marc Ferrer-Alegre
• 金额: $ 4.76万
• 依托单位: NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10006269
• 关键词: 3-Dimensional; Biological Assay; Cells; Collaborations; Communities; Complex; Development; Disease; Extramural Activities; Fostering; General Population; Growth; Informatics; Malignant neoplasm of ovary; Modeling; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phenotype; Physiological; Publications; Research; Research Personnel; Resources; United States National Institutes of Health; Work; cancer cell; drug discovery; high throughput screening; human disease; improved; novel therapeutics; response; screening; small molecule; three-dimensional modeling; tumor

During this period, the collaborative team is working to further characterize identified hits from the previously completed primary screen in secondary assays. As a center, the NCGC has fostered and maintained over 130 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.

在此期间，协作团队正在努力进一步表征在二次分析中先前完成的初级筛选中识别出的命中。 作为一个中心，NCGC 与 NIH 和校外研究人员建立并维持了 130 多项积极合作，促进了整个人类疾病范围的药物发现工作。 这些努力导致了数十次高通量筛选和许多药物化学活动，以进一步提高筛选命中率，为我们的合作者和一般研究界提供出版物和各种有前途的小分子探针和先导化合物。 此外，NCGC还致力于推进多项信息化举措，以更好地利用现有药物和疾病靶点信息，为公众提供易于获取的资源，进一步促进人类疾病新疗法的开发。